1291 related articles for article (PubMed ID: 33971067)
1. Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19.
Çolak Ş; Genç Yavuz B; Yavuz M; Özçelik B; Öner M; Özgültekin A; Şenbayrak S
Int J Clin Pract; 2021 Aug; 75(8):e14321. PubMed ID: 33971067
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
Ghati N; Roy A; Bhatnagar S; Bhati S; Bhushan S; Mahendran M; Thakur A; Tiwari P; Dwivedi T; Mani K; Gupta R; Mohan A; Garg R; Saxena A; Guleria R; Deepti S
Trials; 2020 Oct; 21(1):902. PubMed ID: 33126910
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
5. Ozone as an adjuvant therapy for COVID-19: A systematic review and meta-analysis.
Setyo Budi D; Fahmi Rofananda I; Reza Pratama N; Sutanto H; Sukma Hariftyani A; Ratna Desita S; Zinedinita Rahmasari A; Pudy Asmarawati T; Agung Waskito L; Dyah Kencono Wungu C
Int Immunopharmacol; 2022 Sep; 110():109014. PubMed ID: 35803132
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
7. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
8. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
[TBL] [Abstract][Full Text] [Related]
9. Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial.
Araimo F; Imperiale C; Tordiglione P; Ceccarelli G; Borrazzo C; Alessandri F; Santinelli L; Innocenti GP; Pinacchio C; Mauro V; Recchia GE; Zancla S; Calò A; Poscia R; Ruberto F; d'Ettorre G; Bilotta F; Mastroianni C; Pugliese F
J Med Virol; 2021 Apr; 93(4):2210-2220. PubMed ID: 33111980
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of medical ozone therapy in COVID-19: the evidence and gaps map.
Serra MEG; Baeza-Noci J; Abdala CVM; Luvisotto MM; Bertol CD; Anzolin AP
Med Gas Res; 2023; 13(4):172-180. PubMed ID: 37077114
[TBL] [Abstract][Full Text] [Related]
11. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
12. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.
Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V
Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452
[TBL] [Abstract][Full Text] [Related]
13. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
14. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
15. Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial.
Dengiz E; Özcan Ç; Güven Yİ; Uçar S; Ener BK; Sözen S; Yağcı B; Güzel İA; Yiğit B; Andaç A; Güneş B; Bor E; Karabudak U; Kaya A
Med Gas Res; 2022; 12(2):55-59. PubMed ID: 34677153
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for severe outcomes for COVID-19 patients hospitalised in Switzerland during the first pandemic wave, February to August 2020: prospective observational cohort study.
Maximiano Sousa F; Roelens M; Fricker B; Thiabaud A; Iten A; Cusini A; Flury D; Buettcher M; Zukol F; Balmelli C; Zimmermann P; Troillet N; Vuichard-Gysin D; Schreiber PW; Bernhard-Stirnemann S; Tschudin-Sutter S; Nussbaumer-Ochsner Y; Sommerstein R; Gaudenz R; Marschall J; Senn L; Gardiol C; Keiser O; Schüpbach G; Wymann M; Vidondo B; Ch-Sur Study Group
Swiss Med Wkly; 2021 Jul; 151():w20547. PubMed ID: 34324698
[TBL] [Abstract][Full Text] [Related]
17. Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.
Muller M; Lefebvre F; Harlay ML; Glady L; Becker G; Muller C; Aberkane O; Tawk M; Julians M; Romoli A; Hecketsweiler S; Schneider F; Pottecher J; Chamaraux-Tran TN
Trials; 2021 Feb; 22(1):131. PubMed ID: 33573681
[TBL] [Abstract][Full Text] [Related]
18. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
Faqihi F; Alharthy A; Alodat M; Asad D; Aletreby W; Kutsogiannis DJ; Brindley PG; Karakitsos D
Trials; 2020 Jun; 21(1):506. PubMed ID: 32513290
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
